Vertex Pharmaceuticals, Inc. (VRTX) Blows Up Q3 Estimates
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $508.34 -1.55%
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vortex Energy agrees to buy Saskatchewan mineral permit for C$255,000
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
